Incidence and cost of stroke and hemorrhage in patients diagnosed with atrial fibrillation in France.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of Stroke & Cerebrovascular Diseases

• Publication date

  2014-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jstrokecerebrovasdis.2013.08.022PMID 24119623
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Systematic Review of Cost-Effectiveness Models

  2013cited by this paper
• Application of New French Guidelines for Economic Evaluations: A Cost-Effectiveness Analysis of Apixaban in Patients with Non-Valvular Atrial Fibrillation in France

  2013cited by this paper
• Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients.

  2013cited by this paper
• ARISTOTLE RE-LYs on the ROCKET. What's new in stroke prevention in patients with atrial fibrillation?

  2012cited by this paper
• Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation.

  2012cited by this paper
• 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association.

  2012cited by this paper
• Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation

  2012cited by this paper
• PCV17 A Cross-Sectional Assessment of Atrial Fibrillation Management Among French Patients in Primary Care

  2012cited by this paper
• 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association.

  2012cited by this paper
• Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials

  2012cited by this paper
• Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

  2012cited by this paper
• Cost-Effectiveness of Apixaban Compared with Warfarin for Stroke Prevention in Atrial Fibrillation

  2012cited by this paper
• Long-Term Costs of Ischemic Stroke and Major Bleeding Events among Medicare Patients with Nonvalvular Atrial Fibrillation

  2012cited by this paper
• An Update on the Prognosis of Patients With Atrial Fibrillation

  2012cited by this paper
• The cost of illness of atrial fibrillation: a systematic review of the recent literature.

  2011cited by this paper
• Apixaban versus warfarin in patients with atrial fibrillation.

  2011cited by this paper
• Estimation of Total Incremental Health Care Costs in Patients With Atrial Fibrillation in the United States

  2011cited by this paper
• Cost Efficiency of Anticoagulation With Warfarin to Prevent Stroke in Medicare Beneficiaries With Nonvalvular Atrial Fibrillation

  2011cited by this paper
• Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

  2011cited by this paper
• Epidemiology of atrial fibrillation in France: extrapolation of international epidemiological data to France and analysis of French hospitalization data.

  2011cited by this paper
• Characteristics and management of outpatients with history of or current atrial fibrillation: the observational French EPHA study.

  2010cited by this paper
• Costs of Stroke Using Patient-Level Data: A Critical Review of the Literature

  2009cited by this paper
• Dabigatran versus warfarin in patients with atrial fibrillation.

  2009cited by this paper
• Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation.

  2008cited by this paper
• Death and disability from warfarin-associated intracranial and extracranial hemorrhages.

  2007cited by this paper
• Economic burden of cardiovascular diseases in the enlarged European Union.

  2006cited by this paper
• Contribution of Atrial Fibrillation to Incidence and Outcome of Ischemic Stroke: Results From a Population-Based Study

  2005cited by this paper
• Cost of care distribution in atrial fibrillation patients: the COCAF study.

  2004cited by this paper
• Cost of care distribution in atrial fibrillation patients: the COCAF study

  2004cited by this paper
• Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation.

  2001cited by this paper
• Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation

  2001cited by this paper
• Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study.

  2001cited by this paper
• Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates.

  1998cited by this paper
• Impact of atrial fibrillation on the risk of death: the Framingham Heart Study.

  1998cited by this paper
• Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.

  1991cited by this paper
• Original Contribution

  1989cited by this paper

• Nationwide extrapolation of economic benefit of therapeutic innovation: a 10-year retrospective budget impact of direct oral anticoagulants introduction in France

  2025cites this paper
• Clinical and economic impact of first-line or drug-naïve catheter ablation and delayed second-line catheter ablation for atrial fibrillation using a patient-level simulation model

  2024cites this paper
• Cost-effectiveness of left atrial appendage closure for stroke prevention in atrial fibrillation: a systematic review appraising the methodological quality

  2023cites this paper
• Apixaban versus other anticoagulants in patients with nonvalvular fibrillation: a comparison of all-cause and event-related costs in real-life setting in France

  2022cites this paper
• Carotid Artery Stenting in Patients with Atrial Fibrillation: Direct Oral Anticoagulants, Brief Double Antiplatelets, and Testing Strategy

  2021cites this paper
• Longer length of post-acute care stay causes greater functional improvements in poststroke patients

  2021cites this paper
• Cost-Effectiveness Analysis of SAPIEN 3 Transcatheter Aortic Valve Implantation Procedure Compared With Surgery in Patients With Severe Aortic Stenosis at Low Risk of Surgical Mortality in France.

  2021cites this paper
• Comparison of Cost-Effectiveness between Inpatient and Home-Based Post-Acute Care Models for Stroke Rehabilitation in Taiwan

  2021cites this paper
• Use of real-world evidence in meta-analyses and cost-effectiveness models

  2020cites this paper
• Terapia de Anticoagulação em Pacientes com Fibrilação Atrial não Valvar em Ambiente de Cuidado de Saúde Privado no Brasil: Um Estudo de Mundo Real

  2020cites this paper
• Le coût hospitalier des événements cérébro-vasculaires associés à une fibrillation atriale en France

  2020cites this paper
• Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France

  2020cites this paper
• Anticoagulation Therapy in Patients with Non-valvular Atrial Fibrillation in a Private Setting in Brazil: A Real-World Study

  2020cites this paper
• Cost-effectiveness of combined catheter ablation and left atrial appendage closure for symptomatic atrial fibrillation in patients with high stroke and bleeding risk.

  2020cites this paper
• In-hospital direct costs for thromboembolism and bleeding in Chinese patients with atrial fibrillation

  2018cites this paper
• Real world adherence to oral anticoagulant in non-valvular atrial fibrillation patients in China

  2018cites this paper
• Functional Outcome Measures of Recombinant Tissue Plasminogen Activator–Treated Stroke Patients in the Telestroke Technology

  2018cites this paper
• Validación de la escala de riesgo hemorrágico HAS-BLED en una población hospitalaria de nuestro medio

  2017influential citation
• Hypertension and cardiac arrhythmias: executive summary of a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardí

  2017cites this paper
• Costs of major intracranial, gastrointestinal and other bleeding events in patients with atrial fibrillation – a nationwide cohort study

  2017cites this paper
• Epidemiology and Management of Atrial Fibrillation and Stroke: Review of Data from Four European Countries

  2017cites this paper
• A cost-utility analysis for catheter ablation of atrial fibrillation in combination with warfarin and dabigatran based on the CHADS2 score in Japan.

  2017cites this paper
• Direct oral anticoagulants and digestive bleeding: therapeutic management and preventive measures

  2017cites this paper
• Hypertension and cardiac arrhythmias: a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiologí

  2017cites this paper
• Rehabilitative post-acute care for stroke patients delivered by per-diem payment system in different hospitalization paths: A Taiwan pilot study

  2017cites this paper
• Identifying atrial fibrillation in outpatients initiating oral anticoagulants based on medico‐administrative data: results from the French national healthcare databases

  2017cites this paper
• Modelling projections for the uptake of edoxaban in an European population to 2050: effects on stroke, thromboembolism, and health economics perspectives.

  2016cites this paper
• Coût de la prise en charge des accidents vasculaires cérébraux en France

  2016cites this paper
• The impact of ischaemic stroke on atrial fibrillation-related healthcare cost: a systematic review

  2016cites this paper
• Predictive ability of HAS-BLED, HEMORR2HAGES, and ATRIA bleeding risk scores in patients with atrial fibrillation. A French nationwide cross-sectional study.

  2016cites this paper
• Cause of death in patients with atrial fibrillation admitted to French hospitals in 2012: a nationwide database study

  2015cites this paper
• Burden of stroke and other cardiovascular complications in patients with atrial fibrillation hospitalized in France

  2015cites this paper
• Epidemiology of atrial fibrillation: European perspective

  2014cites this paper
• Race against the clock: overcoming challenges in the management of anticoagulant-associated intracerebral hemorrhage.

  2014cites this paper
• Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin

  2014cites this paper
• Vitamin K antagonist treatment in patients with atrial fibrillation and time in therapeutic range in four European countries.

  2014cites this paper
• Acute Hospital, Community, and Indirect Costs of Stroke Associated With Atrial Fibrillation: Population-Based Study

  2014cites this paper
• A more specific anticoagulation regimen is required for patients after the cox-maze procedure.

  2014cites this paper